Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2022

View Archived Issues

OR6A2 is a therapeutic target for atherosclerosis, researchers unveil

Novel ester prodrugs of E-selectin antagonists with improved PK properties

New ENPP2 inhibitors identified at Suzhou Ark Biopharmaceutical

New PROTACs targeting androgen receptors sythesized at Sichuan Haisco Pharmaceutical

Abbisko Therapeutics discovers EGFR inhibtors

Shenzhen Salubris Pharmaceuticals patents ADAM-TS 5 inhibitors

Vitalixir presents new antidiabetic polypeptides

Researchers identify COPA as a prognostic marker and therapeutic target in cervical cancer

Acute intermittent porphyria treatment targets recombinant PBGD protein to the liver

DDO-02005, a novel potent Kv1.5 potassium channel inhibitor with antiarrhythmic activity

Novel CDK9 inhibitor inhibits osteosarcoma in patient-derived orthotopic xenografts

Loss of miR-15a/miR-16-1 contributes to CLL development

Ethris to advance mRNA-based therapeutics for respiratory diseases

Almirall signs agreements with Ablexis and AliviaMab to support work in dermatology

Celsion's DNA-based approach for SARS-CoV-2 vaccine to be studied in NHP challenge study

Drug cocktail is step up for leg regeneration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...